Exploratory Study of Xolair (Omalizumab)to Improve Outcomes in Patients With COPD and Elevated IgE Levels, and Positive RAST or Skin Prick Tests.

Trial Profile

Exploratory Study of Xolair (Omalizumab)to Improve Outcomes in Patients With COPD and Elevated IgE Levels, and Positive RAST or Skin Prick Tests.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jul 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 27 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top